ArticleJournal of translational medicine2025
Deciphering tumor-intrinsic and immune characteristics in resectable non-small cell lung cancer treated with neoadjuvant pembrolizumab and chemotherapy.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable machine learning for presurgical differentiation of Hürthle cell carcinoma and adenoma: a SHAP-augmented approach.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeoadjuvant chemo-immunotherapy (NCIT) aims to improve surgical and survival outcomes of non-small cell lung cancer (NSCLC) patients. However, the clinical application of NCIT still necessitates coordinated immune and molecular biomarker testing.
methodsWe conducted whole transcriptome sequencing on baseline and surgical samples from 26 patients with stage II-III resectable NSCLC who underwent neoadjuvant pembrolizumab plus chemotherapy followed by surgery. Gene expression and immune cell characteristics in the tumor microenvironment were assessed in relation to pathological complete response (pCR) and patient prognosis.
resultsBaseline pCR tumors were characterized by increased expression of genes related to antigen presentation (HLA-C, HLA-E, B2M), immune checkpoint regulation (BTN3A1, CD274), and innate immunity (HMGB1). Surgical samples from pCR patients showed elevated expression of immune-related genes (IGHD, LILRA6, and ICOSLG) but reduced CEACAM6 expression linked to cell adhesion and tumor progression. During NCIT, plasma cells and resting NK cells declined consistently across pathological groups. Non-pCR patients exhibited greater leukocyte-mediated immunity and higher CD8 + T cell infiltration (P < 0.01) post-treatment, suggestive of a sustained anti-tumor immune response. Baseline MGAT5B expression predicted pathological response (area under the curve: 0.86) and was associated with shorter disease-free survival (DFS; P = 0.03), with a consistent trend for overall survival (OS). Higher CEACAM6 expression in surgical samples was associated with both shorter DFS and OS (P = 0.03 and P = 0.04, respectively). The clinical relevance of MGAT5B and CEACAM6 expression for predicting NCIT response and prognosis was further validated in a clinical validation cohort.
conclusionsOur study identified molecular biomarkers for pathological and survival outcomes, which may inform optimal treatment decision-making, guide postoperative therapy, and improve survival outcomes for stage II-III patients with resectable NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.